Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 5/20 | 0.40 |
| ▸ | PPARA | Q07869 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | AGXT | P21549 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28531579 | 0.96 | SIGMAR1 (0.45) | SIGMAR1POLBL3MBTL1PPARGPPARA | |
| SCHEMBL8421896 | 0.96 | SIGMAR1 (0.45) | SIGMAR1POLBL3MBTL1PPARGPPARA | |
| SCHEMBL28546232 | 0.96 | SIGMAR1 (0.45) | SIGMAR1POLBL3MBTL1PPARGPPARA | |
| Hydrochloric Acid SCHEMBL29223868 | 0.95 | SIGMAR1 (0.48) | SIGMAR1POLBL3MBTL1PPARGPPARA | |
| Hydrochloric Acid SCHEMBL8421889 | 0.95 | SIGMAR1 (0.48) | SIGMAR1POLBL3MBTL1PPARGPPARA | |
| Sulfuric Acid SCHEMBL8422013 | 0.90 | SIGMAR1 (0.43) | SIGMAR1POLBL3MBTL1PPARGPPARA | |
| SCHEMBL10869624 | 0.79 | ACACB (0.38) | IDO1AGXT | |
| SCHEMBL9048125 | 0.79 | FFAR1 (0.51) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29366029 | 0.79 | POLB (0.42) | SIGMAR1POLBL3MBTL1PPARGPPARA | |
| SCHEMBL29416529 | 0.78 | IDO1 (0.41) | SIGMAR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989453-B2 | Method of producing a cyclohexenone oxime ether lithium salt, products which can be obtained using this method, the use thereof and corresponding plant protection agents | BASF AKTIENGESELLSCHAFT (DE) | 2006-01-24 | — | — | US | disclosed |
| EP-1317441-B1 | METHOD FOR PRODUCING A CYCLOHEXENONE OXIME ETHER LITHIUM SALT | BASF AG (DE) | 2005-06-15 | — | — | EP | disclosed |
| US-20040014988-A1 | Method for producing a cyclohexenone oxime ether lithium salt, products which can be obtained using this method, the use thereof and corresponding plant protection agents | BASF AKTIENGESELLSCHAFT (DE) | 2004-01-22 | — | — | US | disclosed |
| EP-1317441-A1 | METHOD FOR PRODUCING A CYCLOHEXENONE OXIME ETHER LITHIUM SALT, PRODUCTS WHICH CAN BE OBTAINED USING THIS METHOD, THE USE THEREOF AND CORRESPONDING PLANT PROTECTION AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002022596-A1 | METHOD FOR PRODUCING A CYCLOHEXENONE OXIME ETHER LITHIUM SALT, PRODUCTS WHICH CAN BE OBTAINED USING THIS METHOD, THE USE THEREOF AND CORRESPONDING PLANT PROTECTION AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014988-A1 | Method for producing a cyclohexenone oxime ether lithium salt, products which can be obtained using this method, the use thereof and corresponding plant protection agents | CYP8B1, PAH, HCN2 | SIGMAR1 2652/4885POLB 1991/4885L3MBTL1 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.